BACE1 and Alzheimer disease: Indeed, given the relatively early character of endolysosomal/dysfunction in AD, and a major reliance of amyloidogenic processing on sorting regulators, future therapeutic efforts should maybe aim to lengthen the fidelity of endosomal transport and degradation, and not only focused on majorly targeting the amyloidogenic enzymes, BACE1 and γ-secretase complexes.